Clinical trial results: A jam-packed calendar. The list of companies with clinical trials expected to read out data before year-end is staggeringly long. The outcomes of these studies, more than anything else, may determine how the entire biotech sector ends 2012. Nothing moves a biotech stock -- up or down -- like important clinical trial data. Phase III studies, all expecting results before the year ends: Amicus Therapeutics' ( FOLD) Amigal in Fabry disease; Biogen Idec's rFactor VIII for hemophilia A, rFactor IX for hemophilia B and dexpramipexole for amyotrophic lateral sclerosis (ALS) or Lou Gehrig's disease and Biomarin Pharmaceuticals' ( BMRN) GALNS for MPS IV also known as Morquio Syndrome. More phase III studies: Acadia Pharmaceuticals' ( ACAD) pimavanserin in Parkinson's psychosis; Celsion's ( CLSN) Thermodox in liver cancer; Clovis Oncology's ( CLVS) CO-101 for pancreatic cancer; Ziopharm's ( ZIOP) palifosfamide for sarcoma; Celgene's ( CELG) Abraxane in melanoma and pancreatic cancer; and Exact Sciences' ( EXAS) Cologuard for colon cancer detection. Like I said, a long list! Some of the most impactful clinical data this fall will likely come from companies presenting updates of studies that have already been presented and caused a stir on Wall Street. Topping this list is Sarepta Therapeutics ( SRPT), which will be presenting additional (48 week) data from its eteplirsen muscular dystrophy study at the World Muscle Society meeting, Oct. 9-13. Vertex Pharmaceuticals ( VRTX) will be a headliner at the cystic fibrosis meeting Oct. 11-13 with a detailed data presentation on the combination of Kalydeco and VX-809. Gilead Sciences ( GILD) is expected to present early "cure rate" data on its all-oral hepatitis C combination therapy of GS-7977 and GS-5885 at the AASLD Liver Meeting in November. Celldex Therapeutics ( CLDX) will present updated results from a phase II study of its immunotherapy CDX-011 at the San Antonio Breast Cancer Symposium in December. Threshold Pharmaceuticals ( THLD) should have survival data from the previously reported phase II study of TH-302 in pancreatic cancer. A more complete list of clinical trials with looming data releases can be read here. Drug launches and other questions: Overlook at your peril. The most important "other question" in 2012 is the resolution of New Chemical Entity (NCE) status for Amarin's ( AMRN) Vascepa. Amarin is winning new patents for the prescription fill oil pill but still needs the market exclusivity that comes with NCE status. The next update is expected on Sept. 14.